MedTrace Logo

Management of Neuromuscular Blocking Agents and Their Antagonism

NCT06238219 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2024-04-19

No results posted yet for this study

Summary

Neuromuscular blocking agents (NMBA) are commonly used in clinical practice during general anesthesia to facilitate induction, intubation and surgery. Some studies have shown that their use can be deleterious if not codified. Recent recommendations concerning their use and antagonization were published in 2023.

Research hypothesis:

Using a single-center, retrospective practice study, we aim to analyze whether the 2023 ASA and ESAIC recommendations are being implemented regarding the use of neuromuscular blocking agents.

Conditions

  • Neuromuscular Blocking Agents
  • Neuromuscular Monitoring

Interventions

DRUG

Neuromuscular Blocking Agent

Administration of any neuromuscular blocking agent for surgery under general anesthesia

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-17
Primary Completion
2024-11-30
Completion
2024-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06238219 on ClinicalTrials.gov